Adriana V. Tibbitts

• OMERS Life Sciences in the $650 million strategic financing of Verona Pharm plc (NASDAQ: VRNA) together with funds managed by Oaktree Capital Management, L.P., consisting of up to US$400 million in term loans and up to US$250 million in funding from the sale of a redeemable capped interest in future ensifentrine-related revenue.
• OMERS Life Sciences in its acquisition of a capped, tiered, declining royalty on direct annual net sales of ORLADEYO® (berotralstat) from BioCryst Pharmaceuticals, Inc. for US$150 million.
• OMERS Life Sciences in the negotiation of a definitive credit facility agreement for BridgeBio Pharma, Inc. with a syndicate of lenders for up to US$750 million in financing.
• Sagard Healthcare in purchasing a 1% royalty in net sales of Tyvaso DPI® (treprostinil) inhalation powder from MannKind Corporation (Nasdaq: MNKD), in exchange for up to US$200 million, including the purchase price of US$150 million and an additional potential milestone payment of up to US$50 million.
• Praxis Precision Medicines, Inc. (NASDAQ: PRAX) in an exclusive collaboration and license agreement with Tenacia Biotechnology (Shanghai) Company, Ltd. for the development and commercialization of ulixacaltamide for the treatment of essential tremor in Greater China.
• Pfizer Inc. in connection with the formation of SpringWorks Therapeutics, including its $103M Series A financing and the license of rights to four Pfizer product candidates.
• The University of Pennsylvania in connection with the formation and $115.5M Series A financing of Passage Bio.
• Pyxis Oncology on its worldwide license agreement with Pfizer Inc. for the development and commercialization of antibody-drug conjugate candidates. 
• MacroGenics, Inc. in connection with its agreement with Eversana to commercialize margetuximab in the United States.
• OPKO, Inc. on its development and commercial licensing agreement with Pfizer Inc.
• OPKO, Inc. on its licensing agreement with Japan Tobacco for the international development and marketing of Rayaldee.
• Kiadis Pharma in connection with the acquisition of CytoSen Therapeutics, Inc.
• Galera Therapeutics on the development of drugs targeting oxygen metabolic pathways in connection with an US$80m royalty financing with Clarus (later acquired by Blackstone).
• DRI Capital in its acquisition from MRC Technology of a portion of its royalty interest in pembrolizumab (marketed by Merck & Co., Inc. as Keytruda®).
• TESARO in its collaboration and license agreement with Janssen Biotech involving niraparib for the treatment of prostate cancer.
• TESARO in its exclusive licensing agreement with Takeda for the commercialization and clinical development of niraparib in Japan.
• New Enterprise Associates and Apple Tree Partners in several venture capital financings of companies at various stages of development.
• The University of Pennsylvania in connection with its exclusive license and collaboration of CAR-T technologies to Novartis.
• Immune Design Corp. in connection with its exclusive licenses to a pharmaceutical company for food allergies and HSV.
• Braeburn Pharmaceuticals on its US$110m mezzanine round of financing led by Wellington Management Company.
• Novartis in its acquisition of GlaxoSmithKline's oncology business and divestiture of its animal health business to Eli Lilly.
• Advising a high-technology company in connection with its life science business ventures, including exclusive licenses and joint ventures, to develop digital health products.

*Some of the above matters were handled prior to joining Sidley.